BACKGROUND: Data from the USA, Australia and Europe suggest that the proportion of patients with schizophrenia prescribed an antipsychotic long-acting injection (LAI) varies from around a quarter to a third. Use of LAIs has been associated with male gender and younger age. AIMS: To characterise the use of LAIs in people with schizophrenia in three clinical settings in the UK. METHOD: The study used audit data from quality improvement programmes conducted by the Prescribing Observatory for Mental Health. RESULTS: Long-acting injections were found to be prescribed for between a quarter and a third of patients, depending on the clinical setting. Flupentixol, risperidone and zuclopenthixol were most commonly prescribed and were combined with an oral antipsychotic in half of cases, frequently constituting high-dose prescribing. The use of LAIs was not consistently associated with age, gender or ethnicity. CONCLUSIONS: Antipsychotic LAIs are commonly prescribed. We did not replicate previous findings with respect to demographic variables associated with their use.
BACKGROUND: Data from the USA, Australia and Europe suggest that the proportion of patients with schizophrenia prescribed an antipsychotic long-acting injection (LAI) varies from around a quarter to a third. Use of LAIs has been associated with male gender and younger age. AIMS: To characterise the use of LAIs in people with schizophrenia in three clinical settings in the UK. METHOD: The study used audit data from quality improvement programmes conducted by the Prescribing Observatory for Mental Health. RESULTS: Long-acting injections were found to be prescribed for between a quarter and a third of patients, depending on the clinical setting. Flupentixol, risperidone and zuclopenthixol were most commonly prescribed and were combined with an oral antipsychotic in half of cases, frequently constituting high-dose prescribing. The use of LAIs was not consistently associated with age, gender or ethnicity. CONCLUSIONS: Antipsychotic LAIs are commonly prescribed. We did not replicate previous findings with respect to demographic variables associated with their use.
Authors: Taishiro Kishimoto; Sohag Sanghani; Mark J Russ; Akeem N Marsh; Joshua Morris; Suparna Basu; Majnu John; John M Kane Journal: Int Clin Psychopharmacol Date: 2017-05 Impact factor: 1.659
Authors: Maxine X Patel; Jane Matonhodze; Mirza K Baig; James Gilleen; Jane Boydell; Frank Holloway; David Taylor; George Szmukler; Tim Lambert; Anthony S David Journal: Ther Adv Psychopharmacol Date: 2011-04
Authors: Robin Emsley; Koksal Alptekin; Jean-Michel Azorin; Fernando Cañas; Vincent Dubois; Philip Gorwood; Peter M Haddad; Dieter Naber; José Manuel Olivares; Georgios Papageorgiou; Miguel Roca; Pierre Thomas; Ludger Hargarter; Andreas Schreiner Journal: Ther Adv Psychopharmacol Date: 2015-12